Life Science Investing Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Life Science Investing Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Life Science Investing Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Life Science Investing Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Life Science Investing Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
pharmaceutical investing ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement
pharmaceutical investing ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID (Pimavanserin)
